Activation of ERK1/2 and cyclin D1 expression in oral tongue squamous cell carcinomas: Relationship between clinicopathological appearances and cell proliferation

Oral Oncology

Volumn 42, Issue 6, 2006, Pages 625-631

  Wang, Lihong ^a,b   Liu, Tingjiao ^c   Nishioka, Mai ^b   Aguirre, Rodelio L ^c   Win, Swe Swe ^d   Okada, Norihiko ^b  

^a Graduate School   (China)

^b Oral health Sciences ^*  (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d University of Dental Medicine   (Myanmar)

Author keywords

Activated ERK1 2; Cell cycle regulation; Cell proliferation; Immunohistochemistry; Oral tongue squamous cell carcinoma

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MOUTH CARCINOMA; MOUTH MUCOSA; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TONGUE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN D1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; JAPAN; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; TONGUE NEOPLASMS;

EID: 33745671633     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.11.002     Document Type: Article

References (42)

1. Lenormand P., Sardet C., Pages G., et al. Growth factors induce nuclear translocation of MAPK kinase (p42 mapk and p44mapk) but not of their activator MAP kinase (p45mapk) in fibroblasts. J Cell Biol 122 (1993) 1079-1088
2. Hagemann C., and Blank J.L. The ups and downs of MEK kinase interactions. Cell Signaling 13 (2001) 863-875
3. Hazzalin C.A., and Mahadevan L.C. MAPK-regulated transcription: a continuously variable gene switch. Nat Rev Mol Cell Biol 3 (2002) 30-40
4. Gille H., Kortenjann M., Thomae O., et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 14 (1995) 951-962
5. Lavoie J.N., L'Allemain G., Brunet A., Pouyssegur J., et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271 (1996) 20608-20616
6. Balmanno K., and Cook S.J. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18 (1999) 3085-3097
7. Mulloy R., Salinas S., Philips A., et al. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 22 (2003) 5387-5398
8. Roovers K., and Assoian R.K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22 (2000) 818-826
9. Cheng M., Sexl V., Sherr C.J., and Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci 95 (1998) 1091-1096
10. Agarwal M.L., Ramana C.V., Hamilton M., et al. Regulation of p53 expression by the RAS-MAP kinase pathway. Oncogene 20 (2001) 2527-2536
11. Denhardt D.T. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J 318 (1996) 729-747
12. Lee Jr. J.T., and McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia (Baltimore) 16 (2002) 486-507
13. Wang L.-H., kulousei K., Lin J., et al. Overexpression of H-ras and pERK1/2 related to lymph node metastasis in squamous cell carcinomas. J Oral Biol 45 (2003) 113-120
14. Mishima K., Yamada E., Masui K., et al. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma. Mod Pathol 11 (1998) 886-891
15. Oka H., Chatani Y., Hoshino R., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55 (1995) 4182-4187
16. Ito Y., Sasaki Y., Horimoto M., et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27 (1998) 951-958
17. Gioeli D., Mandell J.W., Petroni G.R., et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59 (1999) 279-284
18. Adeyinka A., Nui Y., Cherlet T., et al. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8 (2002) 1747-1753
19. Pindborg J.J., Reichart P.A., Smith C.J., et al. Histological typing of cancer and precancer of the oral mucosa (1997), Springer Verlag, Berlin
20. Kasukawa J., Harada H., Shima I., et al. The significance of epidermal growth factor receptor and matrix metalloproteinase-3 in squamous cell carcinoma of the oral cavity. Eur J Cancer B Oral Oncol 32 (1996) 217-221
21. Chang K.W., Sarraj S., Lin S.C., et al. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis 21 (2000) 1441-1451
22. Sakata K. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. J Oral Pathol Med 25 (1996) 302-307
23. Kuo M.Y., Chang H.H., Hahn L.J., et al. Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan. J Oral Pathol Med 24 (1995) 255-260
24. Amundadottir L.T., and Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogences. Oncogene 16 (1998) 737-746
25. Mii S., Khalil R.A., Morgan K.G., et al. Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol 270 (1996) H142-H150
26. Malik S.N., Brattain M., Ghosh P.M., et al. Immunohistochemical demonstration of phospho-akt in high gleason grade prostate cancer. Clin Cancer Res 8 (2002) 1168-1171
27. Bova R.J., Quinn D.I., Nankeris J.S., et al. CyclinD1 and p16INK4A expression predict reduced survival in carcinomas of the anterior tongue. Clin Cancer Res 5 (1999) 2810-2819
28. Carlos de Vicente J., Herrero-Zapatero A., Fresno M.F., et al. Expression of cyclin D1 and Ki-67 in squamous cell carcinomas of the oral cavity: clinicopathological and prognostic significance. Oral Oncol 38 (2002) 301-308
29. Smith B.D., Smith G.L., Carter D., et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127 (2001) 780-785
30. Veness M.J., Morgan G.J., Sathiyaseelan Y., et al. Anterior tongue cancer and the incidence of cervical lymph node metastases with increasing tumour thickness: should elective treatment to the neck be standard practice in all patients. ANZ J Surg 75 (2005) 101-105
31. Yuen A.P., Lam K.Y., Wei W.I., et al. A comparison of the prognostic significance of tumor diameter, length, width, thickness, area, volume, and clinicopathological features of oral tongue carcinoma. Am J Surg 180 (2000) 139-143
32. Lim S.C., Zhang S., Ishii G., et al. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 10 (2004) 166-172
33. Asakage T., Yokose T., Mukai K., et al. Tumor thickness predicts cervical metastasis in patients with stage I/II carcinoma of the tongue. Cancer 82 (1998) 1443-1448
34. Hosal A.S., Unal O.F., and Ayhan A. Possible prognostic value of histopathologic parameters in patients with carcinoma of the oral tongue. Eur Arch Otorhinolaryngol 255 (1998) 216-219
35. Kurokawa H., Yamashita Y., Takeda S., et al. Risk factors for late cervical metastases in patients with stage I or II carcinoma of the tongue. Head Neck 24 (2002) 731-736
36. O-charoenrat P., Pillai G., Patel S., et al. Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol 39 (2003) 386-390
37. Tumuluri V., Thomas G.A., and Fraser L.S. The relationship of proliferating cell density at the invasive tumour front with prognostic and risk factors in human oral squamous cell carcinoma. J Oral Pathol Med 33 (2004) 204-208
38. Jares P., Fernandez P.L., Campo E., et al. PRAD-1/cyclin D1 gene amplificant correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54 (1994) 4813-4817
39. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
40. Weber J.D., Raben D.M., Phillips P.J., et al. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 326 (1997) 61-68
41. Jorgensen K., Holm R., Maelandsmo G.M., et al. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 1 (2003) 5325-5331
42. Huynh H., Do P.T., Nguyen T.H., et al. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int J Oncol 25 (2004) 1839-1847